Stem cell-based regenerative medicine therapies for late-stage liver disease as an alternative to organ transplant.
HepaTx is a Palo Alto-based biotech company developing stem cell-based treatments for end-stage liver disease aimed at replacing the need for organ transplants. Their scalable manufacturing process is designed to make liver regeneration both clinically and economically practical. The company is in the research and development stage with no commercially available product; they invite investment and career inquiries via their website. HepaTx is a product of Hepatx.